Microviable ha recibido el 2025 Microbiome Research Reports High-Impact Paper Award, un reconocimiento a la publicación un artículo científico de revisión de alto impacto publicada en 2025 en la revista Microbiome Research Reports.
Nuestro CTO, David Ríos Covián, PhD, ha liderado esta publicación realizada con otros científicos de Microviable, Pilar Manrique, PhD, Ignacio Montero, PhD, Marta F. Gosende and Noelia Martínez, PhD
In this review, we summarize the influence of the gut microbiota on the development of infectious disease and cancer, which are two of the main targets of microbiome-based therapies currently being developed. We analyze the two-way interaction between the gut microbiota and traditional drugs in order to emphasize the influence of gut microbial composition on drug effectivity and treatment response. We explore the different strategies currently available for modulating this ecosystem to our benefit, ranging from 1st generation intervention strategies to more complex 2nd generation microbiome-based therapies and their regulatory framework. Lastly, we finish with a quick overview of what we believe is the future of these strategies, that is 3rd generation microbiome-based therapies developed with the use of artificial intelligence (AI) algorithms.
Puedes acceder al artículo científico en el siguiente enlace: https://www.oaepublish.com/articles/mrr.2023.80
